AU2011231405A1 - Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media - Google Patents

Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media Download PDF

Info

Publication number
AU2011231405A1
AU2011231405A1 AU2011231405A AU2011231405A AU2011231405A1 AU 2011231405 A1 AU2011231405 A1 AU 2011231405A1 AU 2011231405 A AU2011231405 A AU 2011231405A AU 2011231405 A AU2011231405 A AU 2011231405A AU 2011231405 A1 AU2011231405 A1 AU 2011231405A1
Authority
AU
Australia
Prior art keywords
vegf
jbo
otitis media
hif
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011231405A
Other languages
English (en)
Inventor
Steve D. M. Brown
Michael T. Cheeseman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2011231405A1 publication Critical patent/AU2011231405A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011231405A 2010-03-22 2011-03-18 Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media Abandoned AU2011231405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004761.1A GB201004761D0 (en) 2010-03-22 2010-03-22 Method
GB1004761.1 2010-03-22
PCT/GB2011/000382 WO2011117568A1 (en) 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Publications (1)

Publication Number Publication Date
AU2011231405A1 true AU2011231405A1 (en) 2012-10-04

Family

ID=42228117

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011231405A Abandoned AU2011231405A1 (en) 2010-03-22 2011-03-18 Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Country Status (8)

Country Link
US (1) US20130078260A1 (https=)
EP (1) EP2549989A1 (https=)
JP (1) JP2013522350A (https=)
CN (1) CN102905697A (https=)
AU (1) AU2011231405A1 (https=)
CA (1) CA2793643A1 (https=)
GB (1) GB201004761D0 (https=)
WO (1) WO2011117568A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106669A (zh) * 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
MX2020006435A (es) * 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN112807293B (zh) * 2021-03-01 2023-06-02 青岛大学 甲磺酸去铁胺在制备治疗中耳炎药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
CA2593084C (en) * 2004-12-30 2014-03-18 Bioresponse, Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
WO2008094208A2 (en) * 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics

Also Published As

Publication number Publication date
EP2549989A1 (en) 2013-01-30
US20130078260A1 (en) 2013-03-28
CA2793643A1 (en) 2011-09-29
CN102905697A (zh) 2013-01-30
WO2011117568A1 (en) 2011-09-29
JP2013522350A (ja) 2013-06-13
GB201004761D0 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
Maybin et al. Hypoxia and hypoxia inducible factor-1α are required for normal endometrial repair during menstruation
Wu et al. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models
Ramanathan Jr et al. Sinonasal epithelial cell expression of toll-like receptor 9 is decreased in chronic rhinosinusitis with polyps
Zhu et al. HUWE1 promotes EGFR ubiquitination and degradation to protect against renal tubulointerstitial fibrosis
Chen et al. Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis
US10545134B2 (en) RAC1 inhibitors for the treatment of Alport glomerular disease
JP6941565B2 (ja) がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
Ma et al. IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammation
EP3253211B1 (en) Tacrolimus for use for the treatment of lymphedema
JP2016517401A (ja) 結腸直腸癌を処置する方法
CN106573056A (zh) 用于诊断和治疗炎症性肠病的方法和组合物
EP3220908B1 (en) Compositions and methods for treating endometriosis
US20130078260A1 (en) Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media
Guo et al. YAP as a potential therapeutic target for myofibroblast formation in asthma
Chen et al. Astragalus polysaccharide alleviates oxidative stress and senescence in chondrocytes in osteoarthritis via GCN2/ATF4/TXN axis
Deguchi et al. Suppression of renal crystal formation, inflammation, and fibrosis by blocking oncostatin M receptor β signaling
US20220218662A1 (en) Combined mapk and nampt inhibition for treatment of neuron degeneration
US11357780B2 (en) Methods and compositions relating to the inhibition of IP6K1
Li et al. CDK5 regulates PPARγ/NF-κB signaling to exacerbate obesity-related osteoarthritis via modulating macrophage polarization and chondrocyte apoptosis
US20180092894A1 (en) Treatment of eosinophilic inflammatory disease
Shen et al. Microplastics impair wound healing via NAT10-mediated epigenetic dysregulation of FASN-PI3K/AKT signaling
WO2021081580A1 (en) Treatment of renal cystic disease
US20250270330A1 (en) Treatment of headache disorders with nk3 modulators
Wang et al. Rottlerin Inhibits PKCδ to Attenuate Pulmonary Fibrosis by Suppressing NLRC4/ASC-Mediated Pyroptosis
Yang et al. GSDMD deficiency attenuates BPD by suppressing macrophage pyroptosis and promoting M2 polarization

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period